Last edition
News about "Age-Related Macular Degeneration "
Samsung Bioepis Relaunches Byooviz in US Through Commercial Partnership with Harrow
Samsung Bioepis has relaunched its ophthalmology biosimilar Byooviz in the US through its partnership with Harrow, expanding access to a lower-cost treatment option for patients with retinal diseases, including wet age-related macular degeneration.
Age-related Macular Degeneration | 03/07/2026 | By News Bureau
Celltrion Receives US FDA Approval for EYLEA Biosimilar EYDENZELT
Celltrion has received approval from the US Food and Drug Administration (FDA) for EYDENZELT (aflibercept-boav), a biosimilar to EYLEA (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Age-related Macular Degeneration | 11/10/2025 | By Dineshwori | 340
Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars
Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.
Age-Related Macular Degeneration | 18/07/2025 | By Dineshwori | 365
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy